{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=34",
    "query": {
      "intervention": "Intramuscular vaccine",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 835,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T00:22:04.234Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03058692",
      "title": "Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "Influenza Multimeric-001 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Quadrivalent Recombinant Seasonal Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 120,
      "start_date": "2018-04-09",
      "completion_date": "2019-01-14",
      "has_results": true,
      "last_update_posted_date": "2020-06-18",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 3,
      "location_summary": "Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03058692"
    },
    {
      "nct_id": "NCT01427309",
      "title": "A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "High Dose Trivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 31989,
      "start_date": "2011-09",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-04-20",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 105,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 88 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01427309"
    },
    {
      "nct_id": "NCT00616421",
      "title": "Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Infections"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed meningococcal ACWY vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "2 Years to 10 Years"
      },
      "enrollment_count": 2907,
      "start_date": "2008-03",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2016-02-15",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 52,
      "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00616421"
    },
    {
      "nct_id": "NCT01461096",
      "title": "Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Quadrivalent HPV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Vaccine for Male Participants Only",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Vaccine for Female Participants Only",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "27 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "27 Years and older"
      },
      "enrollment_count": 575,
      "start_date": "2012-03",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 22,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01461096"
    },
    {
      "nct_id": "NCT05272735",
      "title": "HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Hepatitis B Vaccine (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 9,
      "start_date": "2022-12-10",
      "completion_date": "2025-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05272735"
    },
    {
      "nct_id": "NCT04847050",
      "title": "A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor Malignancy",
        "Hematologic Malignancy",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ECG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Antibiotics",
          "type": "OTHER"
        },
        {
          "name": "Anti-viral agents",
          "type": "OTHER"
        },
        {
          "name": "Anti-fungal agent",
          "type": "OTHER"
        },
        {
          "name": "Anti-emetics",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2021-04-28",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04847050"
    },
    {
      "nct_id": "NCT03282240",
      "title": "Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "QIV-HD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed TIV-HD1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational TIV-HD2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 2670,
      "start_date": "2017-09-08",
      "completion_date": "2018-04-19",
      "has_results": true,
      "last_update_posted_date": "2022-04-07",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 36,
      "location_summary": "Anaheim, California • Redding, California • San Diego, California + 29 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03282240"
    },
    {
      "nct_id": "NCT07348692",
      "title": "Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PCV21 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "20vPCV licensed vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 2195,
      "start_date": "2026-01-20",
      "completion_date": "2028-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 14,
      "location_summary": "Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07348692"
    },
    {
      "nct_id": "NCT04611802",
      "title": "A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV Infection",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Initial Vaccination Period)",
          "type": "OTHER"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Crossover Vaccination period)",
          "type": "OTHER"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 33000,
      "start_date": "2020-12-27",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 144,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04611802"
    },
    {
      "nct_id": "NCT01972737",
      "title": "Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Ad5-hGCC-PADRE vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2013-10",
      "completion_date": "2016-01-13",
      "has_results": false,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-11-19T00:22:04.234Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01972737"
    }
  ]
}